The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule
IntroductionAnti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1141794/full |
| _version_ | 1797845555849723904 |
|---|---|
| author | Gretel Naidich Natalia E. Santucci Natalia E. Santucci Stella Maris Pezzotto Stella Maris Pezzotto Stella Maris Pezzotto Eduardo A. Ceccarelli Oscar A. Bottasso Oscar A. Bottasso A. Mario Perichón |
| author_facet | Gretel Naidich Natalia E. Santucci Natalia E. Santucci Stella Maris Pezzotto Stella Maris Pezzotto Stella Maris Pezzotto Eduardo A. Ceccarelli Oscar A. Bottasso Oscar A. Bottasso A. Mario Perichón |
| author_sort | Gretel Naidich |
| collection | DOAJ |
| description | IntroductionAnti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure.MethodsWe attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107-day interval, group D, n=264).Results and conclusionsWhile there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed between-dose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule. |
| first_indexed | 2024-04-09T17:40:56Z |
| format | Article |
| id | doaj.art-ae99cdfc57c2494981e33a2b4827ef49 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-09T17:40:56Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-ae99cdfc57c2494981e33a2b4827ef492023-04-17T05:51:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-04-011410.3389/fimmu.2023.11417941141794The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous scheduleGretel Naidich0Natalia E. Santucci1Natalia E. Santucci2Stella Maris Pezzotto3Stella Maris Pezzotto4Stella Maris Pezzotto5Eduardo A. Ceccarelli6Oscar A. Bottasso7Oscar A. Bottasso8A. Mario Perichón9Centro Unico de Donación, Ablación e Implantación de Organos (CUDAIO), Santa Fe, ArgentinaInstituto de Inmunología Clínica y Experimental de Rosario (IDICER-CONICET-UNR), Rosario, ArgentinaFacultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, ArgentinaInstituto de Inmunología Clínica y Experimental de Rosario (IDICER-CONICET-UNR), Rosario, ArgentinaFacultad de Ciencias Médicas, Universidad Nacional de Rosario, Rosario, ArgentinaConcejo de Investigaciones de la Universidad Nacional de Rosario, Rosario, ArgentinaInstituto de Biología Molecular y Celular de Rosario (IBR-CONICET UNR), Rosario, ArgentinaInstituto de Inmunología Clínica y Experimental de Rosario (IDICER-CONICET-UNR), Rosario, ArgentinaConcejo de Investigaciones de la Universidad Nacional de Rosario, Rosario, ArgentinaCentro Unico de Donación, Ablación e Implantación de Organos (CUDAIO), Santa Fe, ArgentinaIntroductionAnti-COVID vaccination in Argentina was carried out using different protocols and variations in periods between administrations, as well as combinations of different vaccine platforms. Considering the relevance of the antibody response in viral infections, we analyzed anti-S antibodies in healthy people at different points of time following the Sputnik immunization procedure.MethodsWe attended the vaccination centers in the city of Rosario, which had shorter versus longer intervals between both doses. A total of (1021) adults with no COVID-compatible symptoms (throughout the study period) were grouped according to the gap between both vaccine doses: 21 (Group A, n=528), 30 (Group B, n=147), and 70 days (Group C, n=82), as well as an additional group of individuals with heterologous vaccination (Sputnik/Moderna, separated by a 107-day interval, group D, n=264).Results and conclusionsWhile there were no between-group differences in baseline levels of specific antibodies, data collected several weeks after administering the second dose showed that group D had the highest amounts of specific antibodies, followed by values recorded in Groups C, B, and A. The same pattern of group differences was seen when measuring anti-S antibodies at 21 or 180 days after the first and second doses, respectively. Delayed between-dose intervals coexisted with higher antibody titers. This happened even more when using a prime-boost heterologous schedule.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1141794/fullserologyvaccinationsprime-boostSARS-CoV-2antibodies |
| spellingShingle | Gretel Naidich Natalia E. Santucci Natalia E. Santucci Stella Maris Pezzotto Stella Maris Pezzotto Stella Maris Pezzotto Eduardo A. Ceccarelli Oscar A. Bottasso Oscar A. Bottasso A. Mario Perichón The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule Frontiers in Immunology serology vaccinations prime-boost SARS-CoV-2 antibodies |
| title | The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule |
| title_full | The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule |
| title_fullStr | The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule |
| title_full_unstemmed | The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule |
| title_short | The long-term antibody response after SARS-CoV-2 prime-boost vaccination in healthy individuals. The positive influence of extended between-dose intervals and heterologous schedule |
| title_sort | long term antibody response after sars cov 2 prime boost vaccination in healthy individuals the positive influence of extended between dose intervals and heterologous schedule |
| topic | serology vaccinations prime-boost SARS-CoV-2 antibodies |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1141794/full |
| work_keys_str_mv | AT gretelnaidich thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT nataliaesantucci thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT nataliaesantucci thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT eduardoaceccarelli thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT oscarabottasso thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT oscarabottasso thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT amarioperichon thelongtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT gretelnaidich longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT nataliaesantucci longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT nataliaesantucci longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT stellamarispezzotto longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT eduardoaceccarelli longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT oscarabottasso longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT oscarabottasso longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule AT amarioperichon longtermantibodyresponseaftersarscov2primeboostvaccinationinhealthyindividualsthepositiveinfluenceofextendedbetweendoseintervalsandheterologousschedule |